AML only.
RC110 was also awarded Rare Paediatric Disease (RPD) status which entitled RAC to a Priority Review Voucher (PRV) upon registration. These PRV's are worth ~US$100m
https://www.pharmaceutical-technology.com/features/switching-sales-investigating-the-financial-impacts-of-fdas-priority-vouchers/?cf-view
Any word on RPD status @RaceOncology?
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene, page-27
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.010(0.64%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.57 | $108.5K | 68.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2520 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 4960 | 2 |
View Market Depth
| Last trade - 11.43am 16/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |